HALO Share Price

Open 12.09 Change Price %
High 12.09 1 Day -0.10 -0.86
Low 11.51 1 Week 0.16 1.41
Close 11.53 1 Month -0.61 -5.02
Volume 1026362 1 Year -4.89 -29.78
52 Week High 17.78
52 Week Low 6.96
HALO Important Levels
Resistance 2 12.07
Resistance 1 11.85
Pivot 11.71
Support 1 11.21
Support 2 10.99
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Halozyme Therapeutics, Inc. (NASDAQ: HALO)

HALO Technical Analysis 3
As on 9th Dec 2016 HALO Share Price closed @ 11.53 and we RECOMMEND Buy for LONG-TERM with Stoploss of 9.98 & Buy for SHORT-TERM with Stoploss of 11.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
HALO Target for December
1st Target up-side 15.19
2nd Target up-side 17.56
3rd Target up-side 19.93
1st Target down-side 8.43
2nd Target down-side 6.06
3rd Target down-side 3.69
HALO Other Details
Segment EQ
Market Capital 613046848.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.halozyme.com
HALO Address
HALO
11388 Sorrento Valley Road
San Diego, CA 92121
United States
Phone: 858-794-8889
Fax: 858-704-8311
Interactive Technical Analysis Chart Halozyme Therapeutics, Inc. ( HALO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Halozyme Therapeutics, Inc.
HALO Business Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company�s research focuses primarily on human enzymes that alter the extracellular matrix. The Company�s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon Corporation (Intrexon), with three product candidates.